Skip to main content
Virginia-based battery technology company, BTRY, has licensed several electrolyte and thin-film coating technologies, developed at Oak Ridge National Laboratory, to make batteries with increased energy density, at lower cost, and with an improved safety profile in crashes. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Several electrolyte and thin-film coating technologies, developed at Oak Ridge National Laboratory, have been licensed by BTRY, a battery technology company based in Virginia, to make batteries with increased energy density, at lower cost, and with an improved safety profile in crashes.

High voltage power lines carry electricity generated by the Tennessee Valley Authority to ORNL. Credit: Dobie Gillispie/ORNL, U.S. Dept. of Energy

ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.

An artist's rendering of the Ultium Cells battery cell production facility to be built in Spring Hill, Tennessee, which will employ 1,300 people. Recognizing the unique expertise of their organizations, ORNL, TVA, and the Tennessee Department of Economic and Community Development have been working together for several years to bring startups developing battery technologies for EVs and established automotive firms to Tennessee. Credit: Ultium Cells

ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.

Ashleigh Kimberlin and Mikayla Molnar achieve success with a gas-trapping apparatus for Ac-225 production. Credit: ORNL, U.S. Dept. of Energy

In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.

Former ORNL Director Thom Mason presents Tom Kollie with a National Intelligence Meritorious Unit Citation on behalf of James Clapper, former director of national intelligence, and the national intelligence community in June 2017. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

A 25-year career with the U.S. Navy, commanding combat missions overseas, brought Tom Kollie back to where he came from — ready to serve his country in a new way.

 

Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.

As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.

Initially, Kevin Gaddis’s adapted HPIC will be used only for the fourth of six separations in  actinium-225 processing, but he hopes it will later be used for other separations — and other isotopes. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

An Oak Ridge National Laboratory researcher has invented a version of an isotope-separating device that can withstand extreme environments, including radiation and chemical solvents.

Balendra Sutharshan

In the mid-1980s, Balendra Sutharshan moved to Canada from the island nation of Sri Lanka. That move set Sutharshan on a path that had him heading continent-spanning collaborations and holding leadership posts at multiple Department of Energy

Brenda Smith, shown here working with a gas viscometer in her research lab, is one of several people concurrently researching the thermophysical properties of feedstock gas. Their research will support computational researchers who are designing processes to separate isotopes. Credit: Carlos Jones/ORNL, US Dept. of Energy

For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.